Previous close | 37.57 |
Open | 37.71 |
Bid | 37.53 x 1400 |
Ask | 37.55 x 900 |
Day's range | 37.35 - 37.72 |
52-week range | 26.19 - 47.50 |
Volume | |
Avg. volume | 538,088 |
Market cap | 24.755B |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 56.77 |
EPS (TTM) | 0.66 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 44.05 |
Company Announcement COPENHAGEN, Denmark; March 29, 2023 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The vesting of the restricted stock units granted to Jan G. J. van de Winkel and Anthony Pagano will be subject to forward looking performance criteria a
Company Announcement COPENHAGEN, Denmark; March 29, 2023 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2023, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant 90,054 restricted stock units to members of management and employees of the Company and the Company’s subsidiaries and 16,276 warrants to the employees of the Compa
Company Announcement At Genmab A/S’ Annual General Meeting held today March 29, 2023, the Annual Report for 2022 was approvedDischarge was given to the Board of Directors and the Executive Management and the year’s profit was carried forwardThe 2022 Compensation Report was approvedSix members of the Board of Directors were re-electedPricewaterhouseCoopers was re-elected as auditor of the CompanyThe proposals from the Board of Directors on the Board of Directors' remuneration for 2023, the propos